Australia markets close in 2 hours 3 minutes

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.2384+0.0106 (+4.65%)
At close: 04:00PM EST
0.2500 +0.01 (+4.87%)
After hours: 07:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.2278
Open0.2414
Bid0.2452 x 1000
Ask0.2500 x 4000
Day's range0.2288 - 0.2600
52-week range0.1310 - 3.0500
Volume167,665
Avg. volume404,031
Market cap6.671M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-2.1720
Earnings date13 Feb 2023 - 17 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

    HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) S

  • GlobeNewswire

    Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

    HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

    HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying